NEW YORK, July 7, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Laboratory Corp. of America Holdings (NYSE: LH), Agilent Technologies Inc. (NYSE: A), Cigna Corp. (NYSE: CI), St. Jude Medical Inc. (NYSE: STJ) and DaVita, Inc. (NYSE: DVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4497-100free.
--
Laboratory Corp. of America Holdings Analyst Notes
On July 1, 2014, Laboratory Corp. of America Holdings (LabCorp) announced that Conversion Right has been triggered for LabCorp's Zero Coupon Convertible Subordinated Notes due 2021. According to the Company, the holders of the said notes may convert all or a portion of the notes into cash and stock of LabCorp by surrendering their notes at any time during the calendar quarter through the close of business at 5:00 p.m., New York City time, on Tuesday, September 30, 2014. LabCorp informed that upon conversion of Zero Coupon Notes, the Company would be required to pay holders in cash for the accreted principal amount of the securities to be converted, with the remaining amount, if any, to be paid with shares of common stock. The full analyst notes on LabCorp are available to download free of charge at:
http://www.analystsreview.com/Jul-07-2014/LH/report.pdf
--
Agilent Technologies Inc. Analyst Notes
On July 2, 2014, Agilent Technologies Inc. (Agilent Technologies) unveiled the M9099 Waveform Creator 2.0, which provides new waveform segment types that are easily combined into multiple tracks and can be aggregated into one composite waveform. The Company stated that the new release gives new capabilities for engineers working on the development of radars, satellite communications, military radios and the next generation of DOCSIS 3.1 cable modems. According to the Company, the new Release 2.0 of the Waveform Creator software includes features such as an 89600 VSA software recording plug-in, a spectral display, and output plug-ins for easy control of complex instrumentation. Agilent Technologies added that the release also enables building or importing of signals, and adds IQ impairments and noise to simulate real-world environments. The full analyst notes on Agilent Technologies are available to download free of charge at:
http://www.analystsreview.com/Jul-07-2014/A/report.pdf
--
Cigna Corp. Analyst Notes
On July 2, 2014, Cigna Corp. (Cigna) announced that its Cigna Foundation has awarded Achilles International a $100,000 World of Difference grant to fund research into the positive effects of running on the mental and physical health of children with autism. According to the Company, Achilles International has extensive anecdotal evidence showing that how walking and running aid people on the autism spectrum can improve their emotional and physical health. Cigna global Chief Marketing Officer and President of the Cigna Foundation Lisa Bacus commented, "Cigna wants to inspire, champion and celebrate people living on the autism spectrum, whether they're crossing a finish line or taking their first step. The Achilles program is an outstanding opportunity for Cigna to contribute to research on effective ways to improve health for children with autism." The full analyst notes on Cigna are available to download free of charge at:
http://www.analystsreview.com/Jul-07-2014/CI/report.pdf
--
St. Jude Medical Inc. Analyst Notes
On July 2, 2014, St. Jude Medical Inc. (St. Jude Medical) announced that U.S. Food and Drug Administration (FDA) has notified the Company stating that the issues cited in warning letter by FDA relating to the Sylmar, California facility have been addressed. St. Jude Medical, Chairman, President and CEO Dan Starks commented, "We take our responsibility as a medical device manufacturer very seriously. We are encouraged by the resolution of the FDA's warning letter and will continue to work to ensure the highest standards are met across our manufacturing facilities. St. Jude Medical is committed to providing our patients, customers and regulators with products and services that meet or exceed their expectations of safety, high-quality performance, reliability and service." The full analyst notes on St. Jude Medical are available to download free of charge at:
http://www.analystsreview.com/Jul-07-2014/STJ/report.pdf
--
DaVita, Inc. Analyst Notes
On June 24, 2014, DaVita Kidney Care, a division of DaVita, Inc. (DaVita) released the results of its 2014 end stage renal disease Quality Incentive Program (QIP) results, showing that 98.4% of the Company's centers were ranked in the top clinical performance tier. The Company noted that the QIP results show that Davita outperformed other kidney care providers in every category. DaVita HealthCare Partners CEO Kent Thiry remarked, "The QIP results demonstrate that DaVita's holistic, comprehensive care approach works. As part of our culture of continuous improvement, we are working with members of the kidney care community and CMS to improve care for our patients." The full analyst notes on DaVita are available to download free of charge at:
http://www.analystsreview.com/Jul-07-2014/DVA/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
